










Reactogenicity of MenB and 4vMenCV when administered concomitantly
PHAA 18 – June 2018

Dr Alan Leeb
www.smartvax.com.au

SmartVax®





8 MenB and MenACWY - response by age

	MenB alone	MenACWY alone	MenB + MenACWY
Total doses	12,477	33,693	2,634
Percent responded	9,662 (77%)	23,906 (71%)	2,089 (79%)
Age group	Age group	Age group	Age group
2m	251 (3%)	25 (<1%)	91 (4%)
3-5m	542 (6%)	80 (<1%)	175 (8%)
6-11m	1,876 (19%)	279 (1%)	359 (17%)
12m-10y	6,166 (64%)	8,799 (37%)	1,155 (55%)
11-17y	420 (4%)	9,261 (39%)	90 (4%)
>17y	407 (4%)	5,462 (23%)	219 (10%)
Male/Female	5,039 (52%)	11,678 (49%)	1,027 (49%)

SmartVax

8 MenB and MenACWY - response by age

	MenB alone	MenACWY alone	MenB + MenACWY
Total doses	12,477	33,693	2,634
Percent responded	9,662 (77%)	23,906 (71%)	2,089 (79%)
Age group	Age group	Age group	Age group
2m	251 (3%)	25 (<1%)	91 (4%)
3-5m	542 (6%)	80 (<1%)	175 (8%)
6-11m	1,876 (19%)	279 (1%)	359 (17%)
12m-10y	6,166 (64%)	8,799 (37%)	1,155 (55%)
11-17y	420 (4%)	9,261 (39%)	90 (4%)
>17y	407 (4%)	5,462 (23%)	219 (10%)
Male/Female	5,039 (52%)	11,678 (49%)	1,027 (49%)

SmartVax


9



SmartVax

10


Number of Bexsero alone encounters by age to 1 May 2018



SmartVax

11 Reactions reported following Bexsero®


Adverse events reported by parents of recently immunised children, by age at administration



SmartVax

12


Adverse Events Reported, By MenB Dose



SmartVax

13


4vMenCV (ACWY) by brand



SmartVax

14


Number of Meningococcal ACWY alone encounters by age to 1 May 2018



SmartVax

15


ACWY



SmartVax

15


ACWY



SmartVax

16

Reaction rate and Medical Attendance rate by age group for Meningococcal ACWY vaccine by brand to 1 May 18



SmartVax

17


Follow up

	MenB alone	MenACWY alone	MenB + MenACWY
Total doses	12,477	33,693	2,634
Percent responded	9,662 (77%)	23,906 (71%)	2,089 (79%)
Age group	Age group	Age group	Age group
2m	251 (3%)	25 (<1%)	91 (4%)
3-5m	542 (6%)	80 (<1%)	175 (8%)
6-11m	1,876 (19%)	279 (1%)	359 (17%)
12m-10y	6,166 (64%)	8,799 (37%)	1,155 (55%)
11-17y	420 (4%)	9,261 (39%)	90 (4%)
>17y	407 (4%)	5,462 (23%)	219 (10%)
Male/Female	5,039 (52%)	11,678 (49%)	1,027 (49%)

SmartVax

18


Number of concomitant MenB & 4vMenCV - ACWY by age to 1 May 2018



SmartVax

19


Adverse Events Reported, by Vaccine



SmartVax

20


Reactogenicity of MenB vs. MenACWY



SmartVax

21


Febrile Reactions, by Age at Administration



SmartVax

22


AEFI requiring Medical Attendance



SmartVax

23


Medically attended events



SmartVax

24


Other vaccines



SmartVax

25


AEFI after MenB, by Concomitant Vaccination



* Significant at P<0.05

SmartVax

25 AEFI after MenB, by Concomitant Vaccination



* Significant at P < .05

SmartVax®

26 What have we learned ?

MenB is highly reactive

reactivity is independent of –
dose
age
concomitant vaccination

Medical attendance is low

Concomitant vaccination – reactivity is solely dependant on the most reactive vaccine antigen

SmartVax®

